On the Horizon: HER3-Targeted Antibody-Drug Conjugates for Advanced Solid Tumors
Treatments for advanced non-small cell lung cancer (NSCLC) and breast cancer are rapidly advancing. Antibody-drug conjugates (ADCs) offer a novel approach to targeting HER3 as a method of delivering a cytotoxic payload that eliminates tumor cells. These interactive infographic activities provide an overview of HER3-targeted ADCs and up-to-date clinical trial data from recent conferences, as well as expert commentary from oncology clinicians.
This initiative is provided by Paradigm Medical Communications, LLC.